Abstract: The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.

Abstract: The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.

Abstract: The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.

Abstract: The invention relates to a device for providing a cell suspension to an apparatus for treating the cells, wherein the device comprises at least one internal space 16 for holding the suspension, and wherein the internal space 16 is at least partially surrounded by a wall 15. The device further comprises at least one inlet port 2 comprising at least one first opening 3 for introducing the suspension into the internal space 16 and at least one outlet port comprising at least one second opening for removing the suspension from said internal space 16. The inlet port 2 further comprises at least one barrier element 6 bordering the first opening 3 at a side furthest to the wall 15 and is partially arranged between the first opening 3 and the internal space 16.

Abstract: The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.

Abstract: Disclosed is a device for applying an electric field to a suspension of cells, comprising at least one chamber which comprises at least one internal space (40) for holding the suspension, the internal space (40) comprising at least two segments (41, 42), wherein each segment (41, 42) comprises at least one electrode (43, 44) and wherein neighboring electrodes (43, 44) are separated from each other by at least one gap (47) which is at least partially filled with an insulating material (46), and wherein the edges of the electrodes (43, 44) facing each other within the internal space (40) are rounded. Rounding the electrodes' edges facing a neighboring electrode results in a significant reduction of field gradients and thus even of the risk of arcing. Also disclosed is a method in which voltage is applied to at least one active electrode (43, 44) while the electrodes (43, 44, 45) or electrode segments next and/or opposite to the active electrode (43, 44) are set to ground potential.

Abstract: The invention relates to a method and device for controlling a filling level of a suspension of cells, cell derivatives, organelles, sub-cellular particles and/or vesicles within at least one chamber of a device for applying an electric field to the suspension. In order to avoid overfilling of the chamber if multiple electroporation cycles are performed and to achieve exact filling in an environment of unpredictable chamber volume, the amount of suspension filled into the chamber is dynamically limited in the course of several electroporation cycles by determining at least one change of the electrical resistance at the outlet port. The resistance between at least one electrode and a grounding electrode is measured during the filling procedure of each cycle at several points in time. Once a change of resistance is detected, the termination routine is initiated and the filling procedure is finally terminated.

Abstract: The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.

Abstract: The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.

Abstract: The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.

Abstract: The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.

Abstract: The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.

Abstract: The invention relates to a device (1) for applying an electric field to a suspension of cells, cell derivatives, organelles, sub-cellular particles and/or vesicles, comprising at least one chamber (6) which comprises at least two electrodes (4), and at least one separating element (13) which is movable within the chamber (6) between two terminal points (14, 15) and, if it is in a position between the terminal points (14, 15), separates at least one first compartment (26) of the chamber (6) from at least one second compartment (27) of the chamber (6).

Abstract: Disclosed is a method for subjecting adherent cells to at least one electric field, in which the electric field is generated by applying a voltage to at least two active electrodes 63, wherein at least three electrodes 63, 64 are provided, and wherein at least two electrodes 63, 64 are active electrodes 63 when the voltage is applied in order to generate a first electric field, and in which at least one second electric field is generated, wherein at least one of the two previously active electrodes 63 is a potential-free electrode 64 when the voltage is applied. Also disclosed is a device 58 comprising at least three electrodes 63, 64, which are connected to at least one voltage source by means of at least one switching device 59, 60, 61, 62, wherein at least five electrodes 63, 64 are connected to the at least one voltage source by means of four switching devices 59, 60, 61, 62, wherein at least two electrodes 63, 64 are connected to the voltage source by means of a common switching device 59, 60, 61, 62.

Abstract: Disclosed is a method for subjecting adherent cells to at least one electric field, in which the electric field is generated by applying a voltage to at least two active electrodes 63, wherein at least three electrodes 63, 64 are provided, and wherein at least two electrodes 63, 64 are active electrodes 63 when the voltage is applied in order to generate a first electric field, and in which at least one second electric field is generated, wherein at least one of the two previously active electrodes 63 is a potential-free electrode 64 when the voltage is applied. Also disclosed is a device 58 comprising at least three electrodes 63, 64, which are connected to at least one voltage source by means of at least one switching device 59, 60, 61, 62, wherein at least five electrodes 63, 64 are connected to the at least one voltage source by means of four switching devices 59, 60, 61, 62, wherein at least two electrodes 63, 64 are connected to the voltage source by means of a common switching device 59, 60, 61, 62.

Abstract: Disclosed is a device for applying an electric field to a suspension of cells, comprising at least one chamber which comprises at least one internal space (40) for holding the suspension, the internal space (40) comprising at least two segments (41, 42), wherein each segment (41, 42) comprises at least one electrode (43, 44) and wherein neighboring electrodes (43, 44) are separated from each other by at least one gap (47) which is at least partially filled with an insulating material (46), and wherein the edges of the electrodes (43, 44) facing each other within the internal space (40) are rounded. Rounding the electrodes' edges facing a neighboring electrode results in a significant reduction of field gradients and thus even of the risk of arcing. Also disclosed is a method in which voltage is applied to at least one active electrode (43, 44) while the electrodes (43, 44, 45) or electrode segments next and/or opposite to the active electrode (43, 44) are set to ground potential.

Abstract: The invention relates to a device for applying an electric field to a suspension of cells, comprising at least one chamber which comprises at least one internal space (40) for holding the suspension, the internal space (40) comprising at least two segments (41, 42), wherein each segment (41, 42) comprises at least one electrode (43, 44) and wherein neighboring electrodes (43, 44) are separated from each other by at least one gap (47) which is at least partially filled with an insulating material (46), and wherein the edges of the electrodes (43, 44) facing each other within the internal space (40) are rounded. Rounding the electrodes' edges facing a neighboring electrode results in a significant reduction of field gradients and thus even of the risk of arcing. The invention further concerns a method, wherein voltage is applied to at least one active electrode (43, 44) while the electrodes (43, 44, 45) or electrode segments next and/or opposite to the active electrode (43, 44) are set to ground potential.

Abstract: The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.

Abstract: The invention relates to a device (1) for applying an electric field to a suspension of cells, cell derivatives, organelles, sub-cellular particles and/or vesicles, comprising at least one chamber (6) which comprises at least two electrodes (4), and at least one separating element (13) which is movable within the chamber (6) between two terminal points (14, 15) and, if it is in a position between the terminal points (14, 15), separates at least one first compartment (26) of the chamber (6) from at least one second compartment (27) of the chamber (6).

Abstract: The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.